Sandu Pharma.

Who are the top shareholders of the Sandu Pharma.?

The top shareholders of Sandu Pharma are Umesh Bhaskar Sandu with 14.37%, and Sanmark Realty And Finance Private Limited with 5.63%. Individual investors collectively own 35.9% of the shares, with no institutional or mutual fund holdings.

The top shareholders of Sandu Pharma include Umesh Bhaskar Sandu, who holds the highest promoter stake at 14.37%. Additionally, Sanmark Realty And Finance Private Limited is the largest public shareholder with a holding of 5.63%. Individual investors collectively hold 35.9% of the shares. There are no institutional investors or mutual funds currently holding shares in the company.

Who are in the management team of Sandu Pharma.?

As of March 2022, the management team of Sandu Pharma includes Umesh B Sandu (Managing Director), Pratika Mhambray (Company Secretary), and several Non-Executive Directors: Dilip R Salgaocar, Krishna B Deshpande, Madan Laxman Kapre, K Vinay Kumar, Shashank B Sandu, and Shubhada P Sandu. Each member plays a key role in the company's governance and operations.

As of March 2022, the management team of Sandu Pharma includes the following members:<BR><BR>1. Umesh B Sandu - Managing Director<BR>2. Pratika Mhambray - Company Secretary & Compliance Officer<BR>3. Dilip R Salgaocar - Non-Executive & Independent Director<BR>4. Krishna B Deshpande - Non-Executive & Independent Director<BR>5. Madan Laxman Kapre - Non-Executive & Independent Director<BR>6. K Vinay Kumar - Non-Executive & Independent Director<BR>7. Shashank B Sandu - Non-Executive & Non-Independent Director<BR>8. Shubhada P Sandu - Non-Executive & Non-Independent Director<BR><BR>Each member holds a specific role within the organization, contributing to its governance and operations.

What does Sandu Pharma. do?

Sandu Pharmaceuticals Ltd manufactures and trades Ayurvedic medicines, operating as a Micro Cap company since 1985. As of March 2025, it reported net sales of 14 Cr and a market cap of Rs 50 Cr.

Overview:<BR>Sandu Pharmaceuticals Ltd is engaged in the manufacturing and trading of Ayurvedic medicines and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History:<BR>Established in 1985, Sandu Pharmaceuticals Ltd has been involved in the Ayurvedic medicine sector since its inception. The company reported its latest quarterly results for March 2025, showing net sales and net profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 14 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 50 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 32.00 <BR>Industry P/E: 30 <BR>Dividend Yield: 1.55% <BR>Debt-Equity: -0.05 <BR>Return on Equity: 3.71% <BR>Price to Book: 1.19 <BR><BR>Contact Details:<BR>Address: Plot No 25/26/29 & 30, Pilerne Indl Estate Marra Bard Bardez Goa : 403511 <BR>Website: http://www.sandu.in

Has Sandu Pharma. declared dividend?

Sandu Pharmaceuticals Ltd has declared an 8% dividend, amounting to ₹0.80 per share, with an ex-date of September 19, 2024. While recent total returns show declines over shorter periods, the company has experienced substantial gains over the longer term.

Sandu Pharmaceuticals Ltd has declared an 8% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 8%<BR>- Amount per share: ₹0.80<BR>- Ex-date: 19 Sep 2024<BR><BR>Dividend Yield: 1.55%.<BR><BR>Total Returns by Period:<BR>Over the 6-month period, the price return was -12.48%, with a dividend return of 0%, resulting in a total return of -12.48%.<BR><BR>In the 1-year period, the price return was -16.07%, the dividend return was 1.34%, leading to a total return of -14.73%.<BR><BR>For the 2-year period, the price return was -11.88%, the dividend return was 2.55%, culminating in a total return of -9.33%.<BR><BR>During the 3-year period, the price return was -25.96%, with a dividend return of 3.55%, resulting in a total return of -22.41%.<BR><BR>In the 4-year period, the price return was 25.8%, the dividend return was 4.83%, producing a total return of 30.63%.<BR><BR>Over the 5-year period, the price return was 220.0%, with a dividend return of 14.52%, leading to a total return of 234.52%.<BR><BR>Overall, Sandu Pharmaceuticals Ltd has declared a dividend, but the total returns over various periods show a mixed performance, with significant declines in shorter periods and substantial gains over the longer term. The recent dividend declaration may provide some relief to investors amidst the fluctuating returns.

Who are the peers of the Sandu Pharma.?

Sandu Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Transchem, Shelter Pharma, Chandra Bhagat, and Mono Pharmacare. In terms of management risk, growth, and capital structure, Sandu Pharma ranks lower than several peers, with a 1-year return of -9.50%.

Peers: The peers of Sandu Pharma. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Transchem, Shelter Pharma, Chandra Bhagat, Mono Pharmacare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Shelter Pharma, while Good management risk is found at Divi's Lab., Torrent Pharma, and Sandu Pharma. Below Average management risk is present at Chandra Bhagat, Mono Pharmacare, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Sandu Pharma., Chandra Bhagat, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Shelter Pharma, while Good capital structure is found at Torrent Pharma and Sandu Pharma., and Below Average capital structure is present at Transchem, Chandra Bhagat, Mono Pharmacare, and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Chandra Bhagat has the lowest at -42.15%. Sandu Pharma.'s 1-year return is -9.50%, which is lower than both of these peers. Additionally, Transchem, Shelter Pharma, Chandra Bhagat, and Mono Pharmacare all have negative six-month returns.

What is the technical trend for Sandu Pharma.?

As of June 5, 2025, Sandu Pharma's technical trend is mildly bearish, with mixed signals from indicators like the weekly MACD being mildly bullish and the monthly MACD remaining bearish, alongside bearish weekly RSI and daily moving averages.

As of 5 June 2025, the technical trend for Sandu Pharma has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The weekly RSI is bearish, while the monthly RSI shows no signal, suggesting weakness in momentum. Moving averages on the daily chart are mildly bearish, reinforcing the negative sentiment. Bollinger Bands indicate a mildly bullish stance on the weekly but bearish on the monthly, adding to the mixed outlook. The KST is mildly bullish weekly but bearish monthly, and Dow Theory shows a mildly bearish trend on the weekly with no trend on the monthly. Overall, the current stance is mildly bearish, with key indicators like the daily moving averages and the monthly MACD contributing to this view.

How big is Sandu Pharma.?

As of 24th July, Sandu Pharmaceuticals Ltd has a market capitalization of 48.00 Cr, with recent net sales of 67.19 Cr and a net profit of 1.56 Cr. The company reported shareholder's funds of 40.59 Cr and total assets of 52.41 Cr for the annual period ending in March 2024.

As of 24th July, Sandu Pharmaceuticals Ltd has a market capitalization of 48.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sandu Pharmaceuticals reported Net Sales of 67.19 Cr and a Net Profit of 1.56 Cr.<BR><BR>For the latest annual period ending in March 2024, the company had Shareholder's Funds amounting to 40.59 Cr and Total Assets of 52.41 Cr.

Are Sandu Pharma. latest results good or bad?

Sandu Pharmaceuticals' latest results are unfavorable, with a 18.1% decline in net sales and a 41.07% drop in net profit for the quarter ending March 2025, leading to a 'Strong Sell' rating from MarketsMOJO due to serious financial concerns.

The latest results for Sandu Pharmaceuticals indicate a challenging financial performance. For the quarter ending March 2025, the company reported net sales of Rs 14.07 crore, which is a significant decline of 18.1% compared to the average net sales of Rs 17.18 crore over the previous four quarters. This figure represents the lowest net sales for Sandu Pharmaceuticals in the last five quarters.<BR><BR>Additionally, the company's consolidated net profit saw a sharp decrease of 41.07%, reflecting ongoing difficulties in maintaining profitability. The operating profit also experienced a decline of 54.55%. Given these results, MarketsMOJO has issued a 'Strong Sell' rating for the company, indicating serious concerns about its financial health and future prospects.<BR><BR>Overall, the financial results suggest that Sandu Pharmaceuticals is facing significant challenges, making the latest performance appear unfavorable.

When is the next results date for Sandu Pharma.?

The next results date for Sandu Pharma is 12 November 2025.

The next results date for Sandu Pharma is scheduled for 12 November 2025.

How has been the historical performance of Sandu Pharma.?

Sandu Pharma has shown stable financial performance, with net sales slightly decreasing from 67.28 Cr in Mar'24 to 67.19 Cr in Mar'25, while operating profit and profit after tax increased modestly. Total assets rose from 52.41 Cr to 55.72 Cr, indicating consistent asset management.

Answer:<BR>The historical performance of Sandu Pharma shows a relatively stable financial trajectory over the past few years.<BR><BR>Breakdown:<BR>Sandu Pharma's net sales have remained consistent, with a slight decrease from 67.28 Cr in Mar'24 to 67.19 Cr in Mar'25, following a gradual increase from 65.35 Cr in Mar'23 and 65.50 Cr in Mar'22. The total operating income mirrored this trend, reflecting the same figures as net sales. The total expenditure, excluding depreciation, decreased slightly from 64.99 Cr in Mar'24 to 64.43 Cr in Mar'25, contributing to an operating profit (PBDIT) increase from 2.71 Cr to 2.93 Cr during the same period. Profit before tax also saw a modest rise from 2.07 Cr in Mar'24 to 2.16 Cr in Mar'25, while profit after tax increased from 1.46 Cr to 1.55 Cr. The earnings per share (EPS) improved from 1.51 in Mar'24 to 1.6 in Mar'25, although it has decreased from 1.8 in Mar'22. On the balance sheet, total assets rose from 52.41 Cr in Mar'24 to 55.72 Cr in Mar'25, with total liabilities also increasing from 52.41 Cr to 55.72 Cr. The cash flow results indicate a stable cash position, with closing cash and cash equivalents remaining at 1.00 Cr for both Mar'25 and Mar'24. Overall, Sandu Pharma has demonstrated steady performance with slight fluctuations in profitability and consistent asset management.

Is Sandu Pharma. overvalued or undervalued?

As of November 21, 2025, Sandu Pharma is considered undervalued with an attractive valuation grade, featuring a PE ratio of 24.77, an EV to EBITDA of 13.26, and a Price to Book Value of 0.92, significantly lower than its peers, despite a year-to-date stock decline of 30.14% compared to the Sensex's gain of 9.08%.

As of 21 November 2025, the valuation grade for Sandu Pharma has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company is currently assessed as undervalued based on its financial metrics. Key ratios include a PE ratio of 24.77, an EV to EBITDA of 13.26, and a Price to Book Value of 0.92, which suggest that the stock is trading at a reasonable valuation compared to its earnings and asset base.<BR><BR>In comparison to its peers, Sandu Pharma's PE ratio is significantly lower than that of Elitecon International, which stands at 239.98, and MMTC, which has a PE of 133.45. This positions Sandu Pharma favorably within the pharmaceuticals and biotechnology sector, especially when considering its attractive valuation grade. Notably, the company's recent stock performance has lagged behind the Sensex, with a year-to-date decline of 30.14% compared to the Sensex's gain of 9.08%, further reinforcing the notion that it may be undervalued in the current market environment.

Should I buy, sell or hold Sandu Pharmaceuticals Ltd?

Which are the latest news on Sandu Pharma.?

Why is Sandu Pharmaceuticals Ltd falling/rising?

As of 19-Apr, Sandu Pharmaceuticals Ltd's stock price is rising to 38.49, reflecting a 1.42% increase. This short-term gain contrasts with a significant long-term decline of 24.35% over the past year, indicating mixed investor sentiment.

As of 19-Apr, Sandu Pharmaceuticals Ltd's stock price is rising, currently at 38.49, reflecting a change of 0.54 (1.42%) upward. This increase can be attributed to the stock's strong performance over the past week, where it has outperformed the benchmark Sensex by 5.48% compared to the Sensex's 1.22% gain. Additionally, the stock has shown a notable increase of 13.88% over the past month, which further supports the upward trend.<BR><BR>Despite the positive short-term performance, it is important to note that the stock has experienced a significant decline over the longer term, with a 24.35% drop over the past year and a 32.25% decrease over the past three years. However, the current rise in price is also supported by today's performance, where it outperformed its sector by 0.39%. <BR><BR>The stock's moving averages indicate that it is currently higher than the 5-day, 20-day, 50-day, and 100-day moving averages, although it remains lower than the 200-day moving average. This suggests a potential short-term bullish trend, despite the overall long-term challenges reflected in its year-to-date and yearly performance. <BR><BR>However, it is worth mentioning that there has been a significant drop in investor participation, with delivery volume falling by 77.89% against the 5-day average, which could indicate caution among investors. Nonetheless, the current price increase reflects a positive sentiment in the short term.